Registration Dossier

Administrative data

Description of key information

No effects were noted in the key oral and dermal acute toxicity studies and the LD50 in both was greater than 2000 mg/kg, the highest dose tested. 

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
2 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
2 000 mg/kg bw

Additional information

An acute oral toxicity study was performed in rats according to OECD Test Guideline 401 and in compliance with GLP (Hazelton,1987a). An acute dermal toxicity study was performed in rats according to OECD Test Guideline 402 and in compliance with GLP (Hazelton, 1987b).

There were no remarkable findings or mortalities in either the key oral or dermal acute toxicity studies with diphenylsilanediol. Both studies identified the LD50 to be greater than 2000 mg/kg, the highest dose tested.


Justification for selection of acute toxicity – oral endpoint
Study was conducted in accordance with an appropriate guideline and in compliance with GLP.

Justification for selection of acute toxicity – dermal endpoint
Study was conducted in accordance with an appropriate guideline and in compliance with GLP.

Justification for classification or non-classification

Based on the available data diphenylsilanediol does not require classification for acute toxicity according to Regulation (EC) No. 1272/2008.